Aberdeen Group plc Boosts Holdings in Structure Therapeutics Inc. Sponsored ADR $GPCR

Key Points

• Aberdeen Group plc increased its stake in Structure Therapeutics by 45.2%, acquiring an additional 77,511 shares, bringing its total holdings to 248,899 shares valued at approximately $4.3 million.
• Institutional investors collectively own 91.78% of Structure Therapeutics, with notable increases from firms such as Deep Track Capital LP, which raised its position by 129.4% in the fourth quarter.
• Recent analyst reports noted a downward adjustment in price targets for Structure Therapeutics, with JMP Securities lowering it from $89.00 to $87.00 while still maintaining a "market outperform" rating.

Aberdeen Group plc boosted its stake in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Free Report) by 45.2% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 248,899 shares of the company's stock after acquiring an additional 77,511 shares during the period. Aberdeen Group plc owned 0.43% of Structure Therapeutics worth $4,308,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently modified their holdings of GPCR. Janus Henderson Group PLC raised its holdings in shares of Structure Therapeutics by 5.1% in the 4th quarter. Janus Henderson Group PLC now owns 4,159,888 shares of the company's stock worth $112,816,000 after purchasing an additional 203,010 shares during the period. Deep Track Capital LP increased its position in Structure Therapeutics by 129.4% in the fourth quarter. Deep Track Capital LP now owns 2,800,000 shares of the company's stock worth $75,936,000 after buying an additional 1,579,492 shares during the last quarter. Vestal Point Capital LP raised its stake in shares of Structure Therapeutics by 50.0% in the fourth quarter. Vestal Point Capital LP now owns 1,725,000 shares of the company's stock valued at $46,782,000 after buying an additional 575,000 shares during the period. Ameriprise Financial Inc. lifted its position in shares of Structure Therapeutics by 29.4% during the 4th quarter. Ameriprise Financial Inc. now owns 1,420,052 shares of the company's stock valued at $38,512,000 after buying an additional 322,601 shares during the last quarter. Finally, Boxer Capital Management LLC purchased a new position in shares of Structure Therapeutics during the 4th quarter valued at $13,560,000. 91.78% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the company. JMP Securities lowered their price objective on Structure Therapeutics from $89.00 to $87.00 and set a "market outperform" rating on the stock in a research note on Thursday, August 7th. HC Wainwright lowered their price target on shares of Structure Therapeutics from $75.00 to $60.00 and set a "buy" rating on the stock in a research report on Thursday, August 7th. Guggenheim dropped their price target on shares of Structure Therapeutics from $92.00 to $90.00 and set a "buy" rating on the stock in a research note on Thursday, August 7th. Citigroup assumed coverage on shares of Structure Therapeutics in a report on Friday, May 2nd. They issued a "buy" rating and a $60.00 price objective for the company. Finally, Cantor Fitzgerald reissued an "overweight" rating and set a $65.00 target price on shares of Structure Therapeutics in a report on Monday, June 23rd. Eight equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, Structure Therapeutics currently has an average rating of "Buy" and a consensus target price of $75.71.

Structure Therapeutics Trading Down 1.2%

GPCR stock opened at $18.57 on Thursday. The firm has a 50 day moving average of $19.34 and a 200-day moving average of $21.29. Structure Therapeutics Inc. Sponsored ADR has a 12 month low of $13.22 and a 12 month high of $45.37. The firm has a market capitalization of $1.07 billion, a P/E ratio of -17.69 and a beta of -1.89.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported ($0.36) earnings per share for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.08). Sell-side analysts predict that Structure Therapeutics Inc. Sponsored ADR will post -0.82 EPS for the current year.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.

Want to see what other hedge funds are holding GPCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.